首页> 美国卫生研究院文献>PLoS Clinical Trials >EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE)
【2h】

EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE)

机译:EphA4受体酪氨酸激酶是实验性自身免疫性脑脊髓炎(EAE)的发作和疾病严重程度的调节剂。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The EphA4 receptor tyrosine kinase is a major regulator of axonal growth and astrocyte reactivity and is a possible inflammatory mediator. Given that multiple sclerosis (MS) is primarily an inflammatory demyelinating disease and in mouse models of MS, such as experimental autoimmune encephalomyelitis (EAE), axonal degeneration and reactive gliosis are prominent clinical features, we hypothesised that endogenous EphA4 could play a role in modulating EAE. EAE was induced in EphA4 knockout and wildtype mice using MOG peptide immunisation and clinical severity and histological features of the disease were then compared in lumbar spinal cord sections. EphA4 knockout mice exhibited a markedly less severe clinical course than wildtype mice, with a lower maximum disease grade and a slightly later onset of clinical symptoms. Numbers of infiltrating T cells and macrophages, the number and size of the lesions, and the extent of astrocytic gliosis were similar in both genotypes; however, EphA4 knockout mice appeared to have decreased axonal pathology. Blocking of EphA4 in wildtype mice by administration of soluble EphA4 (EphA4-Fc) as a decoy receptor following induction of EAE produced a delay in onset of clinical symptoms; however, most mice had clinical symptoms of similar severity by 22 days, indicating that EphA4 blocking treatment slowed early EAE disease evolution. Again there were no apparent differences in histopathology. To determine whether the role of EphA4 in modulating EAE was CNS mediated or due to an altered immune response, MOG primed T cells from wildtype and EphA4 knockout mice were passively transferred into naive recipient mice and both were shown to induce disease of equivalent severity. These results are consistent with a non-inflammatory, CNS specific, deleterious effect of EphA4 during neuroinflammation that results in axonal pathology.
机译:EphA4受体酪氨酸激酶是轴突生长和星形胶质细胞反应性的主要调节剂,并且可能是炎症介质。鉴于多发性硬化症(MS)主要是一种炎症性脱髓鞘疾病,并且在MS的小鼠模型中,例如实验性自身免疫性脑脊髓炎(EAE),轴突变性和反应性神经胶质增生是主要的临床特征,我们假设内源性EphA4可能在调节中发挥作用EAE。使用MOG肽免疫在EphA4基因敲除和野生型小鼠中诱发EAE,然后在腰脊髓切片中比较该疾病的临床严重性和组织学特征。与野生型小鼠相比,EphA4基因敲除小鼠的临床病程明显减轻,最大疾病等级较低,临床症状发作稍晚。在两种基因型中,浸润性T细胞和巨噬细胞的数量,病变的数量和大小以及星形胶质细胞胶质增生的程度相似。但是,EphA4基因敲除小鼠似乎轴突病理学降低。在诱导EAE后,通过以可溶性EphA4(EphA4-Fc)作为诱饵受体给药来阻断野生型小鼠中的EphA4,会延迟临床症状的发作。但是,大多数小鼠在22天之前具有类似严重程度的临床症状,表明EphA4阻断治疗减缓了早期EAE疾病的发展。再次,组织病理学没有明显差异。为了确定EphA4在调节EAE中的作用是中枢神经系统介导的还是由于免疫应答的改变,将来自野生型和EphA4基因敲除小鼠的MOG引发的T细胞被动转移到幼稚的受体小鼠中,并且都显示出可诱发同等严重程度的疾病。这些结果与导致轴突病理的神经发炎期间EphA4的非炎性,中枢神经系统特异性,有害作用相一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号